|
07 Jan 2019 |
Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria
|
|
07 Jan 2019 |
Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019
|
|
05 Jan 2019 |
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
|
|
05 Jan 2019 |
Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors
|
|
03 Jan 2019 |
Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
|
|
03 Jan 2019 |
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
|
|
03 Jan 2019 |
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
|
|
03 Jan 2019 |
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
|
|
22 Dec 2018 |
Benitec Provides Update on BB-401 Cancer Treatment Program
|
|
22 Dec 2018 |
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
|
|
20 Dec 2018 |
Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of Non-Melanoma Skin Cancer
|
|
20 Dec 2018 |
Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
|
|
20 Dec 2018 |
Exicure Announces Top-line Patient Data for Phase 1 Inflammation Program in Psoriasis
|
|
20 Dec 2018 |
Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy
|
|
19 Dec 2018 |
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer
|
|
17 Dec 2018 |
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
|
|
15 Dec 2018 |
NOXXON Announces Key Findings That NOX-A12 Plus Keytruda® Induces an Immune Response and Results in Clinical Benefit for Patients
|
|
14 Dec 2018 |
AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
|
|
14 Dec 2018 |
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
|
|
14 Dec 2018 |
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
|
|
11 Dec 2018 |
XenoTherapeutics to Start First Human Trial of Xeno-Skin™, a Novel Xenotransplantation Treatment for Severe Burns
|
|
11 Dec 2018 |
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
|
|
06 Dec 2018 |
iCell Gene Therapeutics Presents First-in-Human Data of CLL1-CD33 Compound CAR T in Refractory Acute Myeloid Leukemia
|
|
06 Dec 2018 |
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
|
|
05 Dec 2018 |
Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
|
